Non-hodgkin lymphoma
JO Armitage, RD Gascoyne, MA Lunning, F Cavalli - The lancet, 2017 - thelancet.com
Lymphomas can affect any organ in the body, present with a wide range of symptoms, and
be seen by primary care physicians and physicians from most specialties. They are …
be seen by primary care physicians and physicians from most specialties. They are …
Follicular lymphoma: 2020 update on diagnosis and management
A Freedman, E Jacobsen - American journal of hematology, 2020 - Wiley Online Library
Disease overview Follicular lymphoma (FL) is generally an indolent B cell
lymphoproliferative disorder of transformed follicular center B cells. Follicular lymphoma is …
lymphoproliferative disorder of transformed follicular center B cells. Follicular lymphoma is …
Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis …
C Casulo, M Byrtek, KL Dawson, X Zhou… - Journal of Clinical …, 2015 - ascopubs.org
Purpose Twenty percent of patients with follicular lymphoma (FL) experience progression of
disease (POD) within 2 years of initial chemoimmunotherapy. We analyzed data from the …
disease (POD) within 2 years of initial chemoimmunotherapy. We analyzed data from the …
Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study
PURPOSE The PRIMA study (ClinicalTrials. gov identifier: NCT00140582) established that 2
years of rituximab maintenance after first-line immunochemotherapy significantly improved …
years of rituximab maintenance after first-line immunochemotherapy significantly improved …
Follicular lymphoma: 2023 update on diagnosis and management
E Jacobsen - American Journal of Hematology, 2022 - Wiley Online Library
Abstract Disease Overview Follicular lymphoma (FL) is generally an indolent B cell
lymphoproliferative disorder of transformed follicular center B cells. FL is characterized by …
lymphoproliferative disorder of transformed follicular center B cells. FL is characterized by …
Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a …
ME Goebeler, S Knop, A Viardot, P Kufer… - Journal of Clinical …, 2016 - ascopubs.org
Purpose Blinatumomab is a CD19/CD3 BiTE (bispecific T-cell engager) antibody construct
for the treatment of Philadelphia chromosome–negative acute B-lymphoblastic leukemia …
for the treatment of Philadelphia chromosome–negative acute B-lymphoblastic leukemia …
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a …
LH Sehn, N Chua, J Mayer, G Dueck, M Trněný… - The Lancet …, 2016 - thelancet.com
Background Patients with indolent non-Hodgkin lymphoma who fail to achieve adequate
disease control with rituximab-based treatment have few treatment options and a poor …
disease control with rituximab-based treatment have few treatment options and a poor …
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
Background Endogenous or iatrogenic antitumour immune responses can improve the
course of follicular lymphoma, but might be diminished by immune checkpoints in the tumour …
course of follicular lymphoma, but might be diminished by immune checkpoints in the tumour …
Pathogenesis of follicular lymphoma
R Kridel, LH Sehn, RD Gascoyne - The Journal of clinical …, 2012 - Am Soc Clin Investig
The hallmark t (14; 18)(q32; q21) in follicular lymphoma (FL) results in constitutive
overexpression of the BCL2 protein, allowing B cells to abrogate the default germinal center …
overexpression of the BCL2 protein, allowing B cells to abrogate the default germinal center …
Early event status informs subsequent outcome in newly diagnosed follicular lymphoma
Recent advances in follicular lymphoma (FL) have resulted in prolongation of overall
survival (OS). Here we assessed if early events as defined by event‐free survival (EFS) at 12 …
survival (OS). Here we assessed if early events as defined by event‐free survival (EFS) at 12 …